A U.S. appeals court has ruled in Sanofi’s (SNY +1.4%) favor related to its infringement dispute with Indian generic drug maker Zydus Cadila over two patents covering blood cancer med Mozobil (plerixafor injection).
Zydus conceded infringement on the patents, which expire in 2023, but was challenging their validity.
https://seekingalpha.com/news/3492635-sanofi-prevails-appeal-mozobil-patents
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.